董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Douglas Deeth | 男 | Director | 76 | 41.66万美元 | 未持股 | 2017-03-15 |
| Jordan Kupinsky | 男 | Director | 51 | 44.41万美元 | 未持股 | 2017-03-15 |
| Rochelle Fuhrmann | 女 | Director | 54 | 7.20万美元 | 未持股 | 2017-03-15 |
| Allan Oberman | 男 | Chief Executive Officer and a Director | 66 | 未披露 | 未持股 | 2017-03-15 |
| Patrick Vink | 男 | Director | 61 | 未披露 | 未持股 | 2017-03-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Wayne Kreppner | 男 | President and Chief Operating Officer | -- | 689.24万美元 | 未持股 | 2017-03-15 |
| Francesco Tallarico | 男 | Chief Legal Officer and Secretary | -- | 352.59万美元 | 未持股 | 2017-03-15 |
| Edward Borkowski | 男 | Chief Financial Officer | 64 | 6.67万美元 | 未持股 | 2017-03-15 |
| Adeel Ahmad | 男 | Chief Financial Officer of the Concordia International segment | -- | 未披露 | 未持股 | 2017-03-15 |
| Arijit Mookerjee | 男 | Managing Director and Chief Financial Officer of CPI and CLI | -- | 未披露 | 未持股 | 2017-03-15 |
| Graeme Duncan | 男 | President of the Concordia International segment | -- | 未披露 | 未持股 | 2017-03-15 |
| Allan Oberman | 男 | Chief Executive Officer and a Director | 66 | 未披露 | 未持股 | 2017-03-15 |
董事简历
中英对照 | 中文 | 英文- Douglas Deeth
-
Douglas Deeth，现为法律公司Deeth Williams Wall LLP的合伙人。他是 Canadian Bar Association知识产权法分会的前会长，在制药行业有着超过35年的工作经验。他一直被一些国际影响刊物称为是加拿大著名的知识产权律师之一；他有着丰富的诉讼经历，尤擅长于授权、产品开发协议的谈判和达成。他为客户提供及时、现实、务实的建议，涉及所有形式技术及知识产权的清理、保护、实施，尤其在化学和制药的相关产品和工艺方面，有特别的专长。1976年，他加入Bar of Ontario，有着超过35年的诉讼经验，从最复杂的知识产权诉讼，到司法审查程序、审禁制令申请。他经常在加拿大联邦法庭和安大略省法庭出庭。1970年，他在 University of Waterloo获得化学工程学士学位；1974年，在University of Toronto获得法律学士学位；在知识产权法领域，从事过教学、写作、演讲等活动。他曾在下列机构讲课：McMaster University、 the University of Toronto 、Osgoode Hall law schools 、the McGill courses on Patent and Copyright Law。
Douglas Deeth is a partner with the law firm of Deeth Williams Wall LLP. He is the former President of the Intellectual Property Law section of the Canadian Bar Association, the current President of the International Federation of Intellectual Property Attorneys FICPI and has over 35 years of experience working with the pharmaceutical industry. Throughout most of his career Mr. Deeth has been extensively involved in product acquisition and licensing agreements in the pharmaceutical field. He was directly involved in almost all of the product and technology acquisition and license agreements of Biovail Corporation from its inception in 1987 until 2008. Mr. Deeth has been recognized in several international reviews as one of Canada's leading intellectual property lawyers. He was a director of Trimel Pharmaceuticals Inc., and is on the board of IM Biotechnologies Inc. Mr. Deeth was admitted to the Bar of Ontario in 1976. He has a B.A.Sc. in Chemical Engineering from the University of Waterloo -1970 and an LL.B. from the University of Toronto -1974 and has taught, written and spoken extensively on intellectual property law. He has lectured at McMaster University, the University of Toronto and Osgoode Hall law schools and the McGill courses on Patent and Copyright Law. - Douglas Deeth，现为法律公司Deeth Williams Wall LLP的合伙人。他是 Canadian Bar Association知识产权法分会的前会长，在制药行业有着超过35年的工作经验。他一直被一些国际影响刊物称为是加拿大著名的知识产权律师之一；他有着丰富的诉讼经历，尤擅长于授权、产品开发协议的谈判和达成。他为客户提供及时、现实、务实的建议，涉及所有形式技术及知识产权的清理、保护、实施，尤其在化学和制药的相关产品和工艺方面，有特别的专长。1976年，他加入Bar of Ontario，有着超过35年的诉讼经验，从最复杂的知识产权诉讼，到司法审查程序、审禁制令申请。他经常在加拿大联邦法庭和安大略省法庭出庭。1970年，他在 University of Waterloo获得化学工程学士学位；1974年，在University of Toronto获得法律学士学位；在知识产权法领域，从事过教学、写作、演讲等活动。他曾在下列机构讲课：McMaster University、 the University of Toronto 、Osgoode Hall law schools 、the McGill courses on Patent and Copyright Law。
- Douglas Deeth is a partner with the law firm of Deeth Williams Wall LLP. He is the former President of the Intellectual Property Law section of the Canadian Bar Association, the current President of the International Federation of Intellectual Property Attorneys FICPI and has over 35 years of experience working with the pharmaceutical industry. Throughout most of his career Mr. Deeth has been extensively involved in product acquisition and licensing agreements in the pharmaceutical field. He was directly involved in almost all of the product and technology acquisition and license agreements of Biovail Corporation from its inception in 1987 until 2008. Mr. Deeth has been recognized in several international reviews as one of Canada's leading intellectual property lawyers. He was a director of Trimel Pharmaceuticals Inc., and is on the board of IM Biotechnologies Inc. Mr. Deeth was admitted to the Bar of Ontario in 1976. He has a B.A.Sc. in Chemical Engineering from the University of Waterloo -1970 and an LL.B. from the University of Toronto -1974 and has taught, written and spoken extensively on intellectual property law. He has lectured at McMaster University, the University of Toronto and Osgoode Hall law schools and the McGill courses on Patent and Copyright Law.
- Jordan Kupinsky
-
Jordan Kupinsky，现为JJR Private Capital的总裁；2008年以来，一直任职于JJR.2011年1月至2014年7月，他还曾担任Windsor Private Capital的董事总经理，这是一个私募股权商人银行公司。加入JJR Private Capital之前，2006年3月至2008年5月，他担任Greenhill & Co.的副总裁，这是在纽交所上市的独立的全球性投资银行公司，专注于并购、财务重组。加入Greenhill & Co.之前，2002年7月至2005年2月，他是上市公司Minacs Worldwide Inc.的企业发展副总裁、法律总顾问。职业生涯之初，他在Torys LLP从事公司和证券法律执业，任期1997-1999；1999-2002，还曾是Houlihan Lokey Howard & Zukin的投资银行助理。他在Schulich School of Business and Osgoode Hall Law School at York University获得工商管理硕士与法律博士的联合学位。他现为Atlas Financial Holdings Inc.、Mira IV Acquisition Corp的董事。他曾从2012年5月起，曾担任Xceed Mortgage Corporation的董事，直到2013年7月该公司被出售给MCAN Mortgage Corporation。
Jordan Kupinsky is the Non-Executive Chairman of the Board. Mr. Kupinsky is the President of Justley Capital Corporation, a private investment and advisory firm. From April 2008 through September 2016 Mr. Kupinsky was a partner with JJR Private Capital. For part of that time January 2011 through July 2014 Mr. Kupinsky was also Managing Director with Windsor Private Capital, a private merchant banking firm. Mr. Kupinsky was a Vice President at Greenhill & Co., an independent global investment banking firm, listed on the NYSE, focused on mergers and acquisitions and financial restructuring from March 2006 to May 2008. Prior to joining Greenhill, Mr. Kupinsky held the positions of Vice President of Corporate Development and General Counsel at Minacs Worldwide Inc., a publicly traded company on the TSX from July 2002 to February 2005. Mr. Kupinsky began his career practicing corporate and securities law at Torys LLP in Toronto from 1997 to 1999 and was also an investment banking associate at Houlihan Lokey Howard & Zukin from 1999 to 2002. He holds a joint MBA and JD degree from the Schulich School of Business and Osgoode Hall Law School at York University. Mr. Kupinsky is currently a director of Atlas Financial Holdings Inc. Mr. Kupinsky has also served as a director of Perk Inc. and Xceed Mortgage Corporation. - Jordan Kupinsky，现为JJR Private Capital的总裁；2008年以来，一直任职于JJR.2011年1月至2014年7月，他还曾担任Windsor Private Capital的董事总经理，这是一个私募股权商人银行公司。加入JJR Private Capital之前，2006年3月至2008年5月，他担任Greenhill & Co.的副总裁，这是在纽交所上市的独立的全球性投资银行公司，专注于并购、财务重组。加入Greenhill & Co.之前，2002年7月至2005年2月，他是上市公司Minacs Worldwide Inc.的企业发展副总裁、法律总顾问。职业生涯之初，他在Torys LLP从事公司和证券法律执业，任期1997-1999；1999-2002，还曾是Houlihan Lokey Howard & Zukin的投资银行助理。他在Schulich School of Business and Osgoode Hall Law School at York University获得工商管理硕士与法律博士的联合学位。他现为Atlas Financial Holdings Inc.、Mira IV Acquisition Corp的董事。他曾从2012年5月起，曾担任Xceed Mortgage Corporation的董事，直到2013年7月该公司被出售给MCAN Mortgage Corporation。
- Jordan Kupinsky is the Non-Executive Chairman of the Board. Mr. Kupinsky is the President of Justley Capital Corporation, a private investment and advisory firm. From April 2008 through September 2016 Mr. Kupinsky was a partner with JJR Private Capital. For part of that time January 2011 through July 2014 Mr. Kupinsky was also Managing Director with Windsor Private Capital, a private merchant banking firm. Mr. Kupinsky was a Vice President at Greenhill & Co., an independent global investment banking firm, listed on the NYSE, focused on mergers and acquisitions and financial restructuring from March 2006 to May 2008. Prior to joining Greenhill, Mr. Kupinsky held the positions of Vice President of Corporate Development and General Counsel at Minacs Worldwide Inc., a publicly traded company on the TSX from July 2002 to February 2005. Mr. Kupinsky began his career practicing corporate and securities law at Torys LLP in Toronto from 1997 to 1999 and was also an investment banking associate at Houlihan Lokey Howard & Zukin from 1999 to 2002. He holds a joint MBA and JD degree from the Schulich School of Business and Osgoode Hall Law School at York University. Mr. Kupinsky is currently a director of Atlas Financial Holdings Inc. Mr. Kupinsky has also served as a director of Perk Inc. and Xceed Mortgage Corporation.
- Rochelle Fuhrmann
-
Rochelle Fuhrmann，本公司的财务高级副总裁，负责企业财务、投资者关系的各种事务。她于2006年6月加入本公司，在2011年1月晋升为高级副总裁之前担任过愈益重要的多个职务，最后的是财务副总裁。加入本公司之前，她在AT&T, Inc.担任过财务、会计、政策、投资者关系、营销领域的各种职务，最后的是会计政策总裁。
Rochelle Fuhrmann has over 20 years of broad financial experience and is currently the Chief Financial Officer, Life Sciences of Becton, Dickinson and Company and was previously the Chief Financial Officer of Amneal. Prior to joining Amneal, Ms. Fuhrmann was Senior Vice President, Finance at Warner Chilcott plc, a specialty pharmaceuticals company, prior to its acquisition by Actavis, Inc. in 2013. She spent the early part of her career in telecommunications and public accounting having held various positions at AT&T and Coopers and Lybrand LLC now PricewaterhouseCoopers LLP. Ms. Fuhrmann earned her certified public accountant designation inactive in 1996 and has a B.Sc. degree in accounting from the University of Rhode Island. - Rochelle Fuhrmann，本公司的财务高级副总裁，负责企业财务、投资者关系的各种事务。她于2006年6月加入本公司，在2011年1月晋升为高级副总裁之前担任过愈益重要的多个职务，最后的是财务副总裁。加入本公司之前，她在AT&T, Inc.担任过财务、会计、政策、投资者关系、营销领域的各种职务，最后的是会计政策总裁。
- Rochelle Fuhrmann has over 20 years of broad financial experience and is currently the Chief Financial Officer, Life Sciences of Becton, Dickinson and Company and was previously the Chief Financial Officer of Amneal. Prior to joining Amneal, Ms. Fuhrmann was Senior Vice President, Finance at Warner Chilcott plc, a specialty pharmaceuticals company, prior to its acquisition by Actavis, Inc. in 2013. She spent the early part of her career in telecommunications and public accounting having held various positions at AT&T and Coopers and Lybrand LLC now PricewaterhouseCoopers LLP. Ms. Fuhrmann earned her certified public accountant designation inactive in 1996 and has a B.Sc. degree in accounting from the University of Rhode Island.
- Allan Oberman
-
Allan Oberman在2012年11月成为Teva Americas Generics的总裁兼首席执行官（在2012年间担任Teva北美仿制药部门的主管之后）。他从2010年至2012年担任Teva EMIA的总裁，负责东欧，中东，以色列和非洲。从2008年到2010年他担任Teva International Group的首席运营官。他从2000年到2008年担任Novopharm Ltd.（目前是Teva Canada）的总裁兼首席执行官。加入Teva之前，他从1996年到2000年是Best Foods Canada Inc.的总裁。他持有约克大学舒立克商学院（Schulich School of Business, York University）的工商管理硕士学位和西安大略大学（University of Western Ontario）的学士学位。
Allan Oberman has been a member of our Board of Directors since March 2019. Mr. Allan Oberman served as the Chief Executive Officer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and as President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Allan Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010 he served as the Chief Operating Officer of the Teva International Group, and from 2000 to 2008 he served as the President and CEO of Teva Canada formerly Novopharm Ltd. From 1996 to 2000 Mr. Allan Oberman was the President of Best Foods Canada Inc. Mr. Allan Oberman was also Vice Chairman of the Association for Accessible Medicines, and Chairman of the Canadian Generic Pharmaceutical Association. He served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. He presently serves on the Board of Planet Shrimp Inc. and Jay Pharma Inc. He holds a MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London. - Allan Oberman在2012年11月成为Teva Americas Generics的总裁兼首席执行官（在2012年间担任Teva北美仿制药部门的主管之后）。他从2010年至2012年担任Teva EMIA的总裁，负责东欧，中东，以色列和非洲。从2008年到2010年他担任Teva International Group的首席运营官。他从2000年到2008年担任Novopharm Ltd.（目前是Teva Canada）的总裁兼首席执行官。加入Teva之前，他从1996年到2000年是Best Foods Canada Inc.的总裁。他持有约克大学舒立克商学院（Schulich School of Business, York University）的工商管理硕士学位和西安大略大学（University of Western Ontario）的学士学位。
- Allan Oberman has been a member of our Board of Directors since March 2019. Mr. Allan Oberman served as the Chief Executive Officer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and as President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Allan Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010 he served as the Chief Operating Officer of the Teva International Group, and from 2000 to 2008 he served as the President and CEO of Teva Canada formerly Novopharm Ltd. From 1996 to 2000 Mr. Allan Oberman was the President of Best Foods Canada Inc. Mr. Allan Oberman was also Vice Chairman of the Association for Accessible Medicines, and Chairman of the Canadian Generic Pharmaceutical Association. He served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. He presently serves on the Board of Planet Shrimp Inc. and Jay Pharma Inc. He holds a MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London.
- Patrick Vink
-
Patrick Vink，2012年9月开始，他就是高级业务部的总经理和高级副总裁。在这之前，他是迈兰公司，（一家由他协调公司所有上市业务的上市制药公司）的医院业务全球主管和生物制品的全球主管和高级副总裁。2008年他加入迈兰，建立了瑞士的公司业务，这是一些全球功能的基础。在加入迈兰前，他在制药公司担任领导职位，包括山德士商业特效经营商业制药公司，诺华制药公司的分部的领导。诺华公司是一家上市全球制药公司。他是Biogen公司的欧洲中部和国际销售副总裁，他是赛诺菲圣德拉堡，（一家全球保健公司）的心血管和血栓形成的全球市场部的董事。
Patrick Vink,has served on Spero Therapeutics, Inc. Board of Directors since September 2015 and currently serves as Spero Therapeutics, Inc. Lead Director, a position he has held since August 2023. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc ("Cubist"). Most recently, he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company's profit and loss. He joined Cubist in 2012 as Senior Vice President and Head of all International Business Operations. In this role, he was responsible for the business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr. Vink serves on the boards of directors of Santhera Pharmaceuticals AG, Amryt Pharma PLC., and is Chairman of the board of directors of two privately held companies. - Patrick Vink，2012年9月开始，他就是高级业务部的总经理和高级副总裁。在这之前，他是迈兰公司，（一家由他协调公司所有上市业务的上市制药公司）的医院业务全球主管和生物制品的全球主管和高级副总裁。2008年他加入迈兰，建立了瑞士的公司业务，这是一些全球功能的基础。在加入迈兰前，他在制药公司担任领导职位，包括山德士商业特效经营商业制药公司，诺华制药公司的分部的领导。诺华公司是一家上市全球制药公司。他是Biogen公司的欧洲中部和国际销售副总裁，他是赛诺菲圣德拉堡，（一家全球保健公司）的心血管和血栓形成的全球市场部的董事。
- Patrick Vink,has served on Spero Therapeutics, Inc. Board of Directors since September 2015 and currently serves as Spero Therapeutics, Inc. Lead Director, a position he has held since August 2023. Dr. Vink has been an advisor to the pharmaceutical industry since 2015 and board member of several companies. Previously, Dr. Vink was employed at Cubist Pharmaceuticals, Inc ("Cubist"). Most recently, he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management and managing the company's profit and loss. He joined Cubist in 2012 as Senior Vice President and Head of all International Business Operations. In this role, he was responsible for the business activities in International markets outside USA. Prior to joining Cubist, Dr. Vink served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, Dr. Vink managed the global hospital business of the company. He joined Mylan in 2008 and established a number of global functions for the company in Switzerland. Before joining Mylan, Dr. Vink held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice President International Business for Biogen, Inc.; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA. Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Dr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his M.B.A. in 1992 from the University of Rochester. Dr. Vink serves on the boards of directors of Santhera Pharmaceuticals AG, Amryt Pharma PLC., and is Chairman of the board of directors of two privately held companies.
高管简历
中英对照 | 中文 | 英文- Wayne Kreppner
Wayne Kreppner，作为的联合创始人、前产品开发副总裁，他曾负责所有的科学运营，包括研发、临床开发、制造与供应链。1997-2008，他在担任了运营、监管事务领域的各种高级职务，参与了产品线的研究、开发、申请、上市工作，其中包括 Wellbutrin XL 、Tiazac。他在University of Western Ontario获得生物化学荣誉学士学位，在McMaster University获得医学硕士学位，在Ivey School of Business, University of Western Ontario获得工商管理硕士学位。
Wayne Kreppner is the President and Chief Operating Officer of the Corporation. Mr. Kreppner has over 20 years of experience as a pharmaceutical operations and R&D executive. A co-founder and former Vice-President of Product Development at Trimel Pharmaceuticals, Mr. Kreppner was responsible for all scientific operations including R&D, clinical development, manufacturing and supply chain. From 1997 to 2008 Mr. Kreppner held various senior roles in operations and regulatory affairs with Biovail Corporation, where he was involved in the discovery, development, approval and launch of the product pipeline including Wellbutrin XL and Tiazac. Mr. Kreppner holds a Hons. B.Sc. degree in Biochemistry from the University of Western Ontario, a M.Sc. in Medical Science from McMaster University and an MBA from the Ivey School of Business, University of Western Ontario.- Wayne Kreppner，作为的联合创始人、前产品开发副总裁，他曾负责所有的科学运营，包括研发、临床开发、制造与供应链。1997-2008，他在担任了运营、监管事务领域的各种高级职务，参与了产品线的研究、开发、申请、上市工作，其中包括 Wellbutrin XL 、Tiazac。他在University of Western Ontario获得生物化学荣誉学士学位，在McMaster University获得医学硕士学位，在Ivey School of Business, University of Western Ontario获得工商管理硕士学位。
- Wayne Kreppner is the President and Chief Operating Officer of the Corporation. Mr. Kreppner has over 20 years of experience as a pharmaceutical operations and R&D executive. A co-founder and former Vice-President of Product Development at Trimel Pharmaceuticals, Mr. Kreppner was responsible for all scientific operations including R&D, clinical development, manufacturing and supply chain. From 1997 to 2008 Mr. Kreppner held various senior roles in operations and regulatory affairs with Biovail Corporation, where he was involved in the discovery, development, approval and launch of the product pipeline including Wellbutrin XL and Tiazac. Mr. Kreppner holds a Hons. B.Sc. degree in Biochemistry from the University of Western Ontario, a M.Sc. in Medical Science from McMaster University and an MBA from the Ivey School of Business, University of Western Ontario.
- Francesco Tallarico
Francesco Tallarico，他是公司的首席法务官兼秘书，以及公司的前任副总裁，负责法律事务（从2014年11月到2015年11月）。他曾管理公司的全球法律顾问。2014年加入公司之前，他曾在Fasken Martineau DuMoulin公司（安大略省多伦多国际律师事务所）从事法律实践，专注于公司治理、企业融资和并购交易。任职公司之前，他也一直积极参与和协助交易价值超过45亿美元的并购。他持有the University of Toronto的学士学位，以及the University of Windsor的法学博士学位。
Francesco Tallarico is the Chief Legal Officer and Secretary of the Corporation. From November 2014 to November 2015 Mr. Tallarico served as the Vice President, Legal Affairs of the Corporation. Mr. Tallarico manages the global legal function of the Corporation. Prior to joining the Corporation in 2014 Mr. Tallarico practiced law at Fasken Martineau DuMoulin LLP, an international law firm based out of Toronto, Ontario, with a particular focus on corporate governance, corporate finance and M&A transactions. During his time with the Corporation, Mr. Tallarico has been actively involved and instrumental in various M&A transactions valued at over $4.5 billion. Mr. Tallarico holds a B.A. from the University of Toronto and a J.D. from the University of Windsor.- Francesco Tallarico，他是公司的首席法务官兼秘书，以及公司的前任副总裁，负责法律事务（从2014年11月到2015年11月）。他曾管理公司的全球法律顾问。2014年加入公司之前，他曾在Fasken Martineau DuMoulin公司（安大略省多伦多国际律师事务所）从事法律实践，专注于公司治理、企业融资和并购交易。任职公司之前，他也一直积极参与和协助交易价值超过45亿美元的并购。他持有the University of Toronto的学士学位，以及the University of Windsor的法学博士学位。
- Francesco Tallarico is the Chief Legal Officer and Secretary of the Corporation. From November 2014 to November 2015 Mr. Tallarico served as the Vice President, Legal Affairs of the Corporation. Mr. Tallarico manages the global legal function of the Corporation. Prior to joining the Corporation in 2014 Mr. Tallarico practiced law at Fasken Martineau DuMoulin LLP, an international law firm based out of Toronto, Ontario, with a particular focus on corporate governance, corporate finance and M&A transactions. During his time with the Corporation, Mr. Tallarico has been actively involved and instrumental in various M&A transactions valued at over $4.5 billion. Mr. Tallarico holds a B.A. from the University of Toronto and a J.D. from the University of Windsor.
- Edward Borkowski
Edward Borkowski，是Concordia Healthcare公司的执行副总裁。加入组织之前，他曾担任健康执行官（始于2013年）。他也曾担任Amerigen Pharmaceuticals公司（一个通用的制药公司，专注于口服控释产品）的首席财务官。任职Amerigen公司之前，他曾担任Mylan N.V。的首席财务官兼执行副总裁。此外，他此前曾担任Convatec公司（全球医疗器械公司，专注于伤口护理和造口术）、Carefusion公司（全球医疗设备公司，在那里他帮助领导公司从Cardinal Health公司中拆分出来成为一个独立的上市公司）的首席财务官。他也曾担任Pharmacia and American Home Products Wyeth公司的高级财务职位。他的职业生涯始于任职Arthur Anderson & Co.。此前，他毕业于Rutgers University，获得会计工商管理硕士学位。他也毕业于Allegheny College，获得经济学和政策科学学位。他是Allegheny College的受托人兼执行委员会成员。他目前是AzurRx BioPharma, Inc.、Transdermal Delivery Solutions Corporation 、WhereverTV Broadcasting Corp.的董事。
Edward Borkowski is the Chief Financial Officer of the Corporation and prior to this role was the Executive Vice President and a director of the Corporation. Mr. Borkowski acted as the CFO of Amerigen Pharmaceuticals, a generic pharmaceutical company with a focus on oral controlled release products. Prior to working with Amerigen, he was the CFO and Executive Vice President of Mylan N.V. In addition, Mr. Borkowski previously held the position of CFO with Convatec, a global medical device company focused on wound care and ostomy, and Carefusion, a global medical device company for which he helped lead its spin-out from Cardinal Health into an independent public company. Mr. Borkowski also held senior financial positions at Pharmacia and American Home Products Wyeth. He started his career with Arthur Andersen & Co. after graduating from Rutgers University with an MBA in accounting. Mr. Borkowski also graduated from Allegheny College with a degree in Economics and Political Science. He is a Trustee and an Executive Committee member of Allegheny College.- Edward Borkowski，是Concordia Healthcare公司的执行副总裁。加入组织之前，他曾担任健康执行官（始于2013年）。他也曾担任Amerigen Pharmaceuticals公司（一个通用的制药公司，专注于口服控释产品）的首席财务官。任职Amerigen公司之前，他曾担任Mylan N.V。的首席财务官兼执行副总裁。此外，他此前曾担任Convatec公司（全球医疗器械公司，专注于伤口护理和造口术）、Carefusion公司（全球医疗设备公司，在那里他帮助领导公司从Cardinal Health公司中拆分出来成为一个独立的上市公司）的首席财务官。他也曾担任Pharmacia and American Home Products Wyeth公司的高级财务职位。他的职业生涯始于任职Arthur Anderson & Co.。此前，他毕业于Rutgers University，获得会计工商管理硕士学位。他也毕业于Allegheny College，获得经济学和政策科学学位。他是Allegheny College的受托人兼执行委员会成员。他目前是AzurRx BioPharma, Inc.、Transdermal Delivery Solutions Corporation 、WhereverTV Broadcasting Corp.的董事。
- Edward Borkowski is the Chief Financial Officer of the Corporation and prior to this role was the Executive Vice President and a director of the Corporation. Mr. Borkowski acted as the CFO of Amerigen Pharmaceuticals, a generic pharmaceutical company with a focus on oral controlled release products. Prior to working with Amerigen, he was the CFO and Executive Vice President of Mylan N.V. In addition, Mr. Borkowski previously held the position of CFO with Convatec, a global medical device company focused on wound care and ostomy, and Carefusion, a global medical device company for which he helped lead its spin-out from Cardinal Health into an independent public company. Mr. Borkowski also held senior financial positions at Pharmacia and American Home Products Wyeth. He started his career with Arthur Andersen & Co. after graduating from Rutgers University with an MBA in accounting. Mr. Borkowski also graduated from Allegheny College with a degree in Economics and Political Science. He is a Trustee and an Executive Committee member of Allegheny College.
- Adeel Ahmad
Adeel Ahmad是AMCO的首席财务官和加拿大的特许专业会计师，注册会计师。成为AMCO的首席财务官之前，2013年12月至2016年2月，Ahmad先生是公司的财务副总裁。2013年加入该公司之前，2012年2月至2013年5月Ahmad先生是Ingram Micro Mobility（Brightpoint的前身）印度业务的财务总监，总部设在印度新德里。在Brightpoint任职之前，2003年至2012年Ahmad先生在Nortel Networks担任越来越重要的财务职务，总部设在 加拿大安大略省布兰普敦；韩国首尔 和中国北京。Ahmad先生在多伦多的Deloitte LLP 开始了他的审计职业生涯。Ahmad先生持有 University of Toronto商学士学位和Ivey School of Business, University of Western Ontario的工商管理硕士学位。
Adeel Ahmad is the Chief Financial Officer of the Concordia International operating segment and is a Chartered Professional Accountant CPA, CA. Prior to becoming the Chief Financial Officer of Concordia International, Mr. Ahmad was Vice President, Finance of the Corporation from December 2013 to February 2016. Prior to joining the Corporation in 2013 Mr. Ahmad was the Chief Financial Officer of the Indian operations of Ingram Micro Mobility formerly BrightPoint, based in New Delhi, India, from February 2012 to May 2013. Prior to his role at BrightPoint, Mr. Ahmad held several finance roles of increasing responsibility with Nortel Networks from 2003 to 2012 based in Brampton, Ontario, Canada; Seoul, South Korea; and Beijing, China. Mr. Ahmad started his career in an audit function with Deloitte LLP in Toronto. Mr. Ahmad holds a B.Comm from the University of Toronto and an MBA from the Ivey School of Business, University of Western Ontario.- Adeel Ahmad是AMCO的首席财务官和加拿大的特许专业会计师，注册会计师。成为AMCO的首席财务官之前，2013年12月至2016年2月，Ahmad先生是公司的财务副总裁。2013年加入该公司之前，2012年2月至2013年5月Ahmad先生是Ingram Micro Mobility（Brightpoint的前身）印度业务的财务总监，总部设在印度新德里。在Brightpoint任职之前，2003年至2012年Ahmad先生在Nortel Networks担任越来越重要的财务职务，总部设在 加拿大安大略省布兰普敦；韩国首尔 和中国北京。Ahmad先生在多伦多的Deloitte LLP 开始了他的审计职业生涯。Ahmad先生持有 University of Toronto商学士学位和Ivey School of Business, University of Western Ontario的工商管理硕士学位。
- Adeel Ahmad is the Chief Financial Officer of the Concordia International operating segment and is a Chartered Professional Accountant CPA, CA. Prior to becoming the Chief Financial Officer of Concordia International, Mr. Ahmad was Vice President, Finance of the Corporation from December 2013 to February 2016. Prior to joining the Corporation in 2013 Mr. Ahmad was the Chief Financial Officer of the Indian operations of Ingram Micro Mobility formerly BrightPoint, based in New Delhi, India, from February 2012 to May 2013. Prior to his role at BrightPoint, Mr. Ahmad held several finance roles of increasing responsibility with Nortel Networks from 2003 to 2012 based in Brampton, Ontario, Canada; Seoul, South Korea; and Beijing, China. Mr. Ahmad started his career in an audit function with Deloitte LLP in Toronto. Mr. Ahmad holds a B.Comm from the University of Toronto and an MBA from the Ivey School of Business, University of Western Ontario.
- Arijit Mookerjee
Arijit Mookerjee，他是CPL公司的董事总经理兼首席财务官。他是the Institute of Chartered Accountants of India FCA的成员、the Institute of Chartered Accountants of Barbados的副合伙人、the Institute of Company Secretaries of India的合格公司秘书。他拥有超过21年的财务会计、管理和审计的领域经验，包括担任4大审计公司的高级职务，以及跨国公司的高级财务管理职务。2015年7月加入公司之前，他曾担任在印度担任 SMEC（澳大利亚工程咨询公司、跨国公司）的南亚和中东金融部门的财务主管，任职2年。此前，他曾担任PricewaterhouseCoopers公司（位于巴巴多斯）的审计主管。他此前曾担任Cordlife公司（干细胞生物技术和医疗集团，位于新加坡和澳大利亚）的集团财务总会计师、KPMG公司（位于阿曼）的审计监察员、KPMG公司（位于新加坡）的高级审计师、Siemens公司（位于印度）的高级账户执行官、Coopers & Lybrand（位于印度）的审计助理。
Arijit Mookerjee is the Managing Director and Chief Financial Officer of CPI. Mr. Mookerjee is a Fellow of the Institute of Chartered Accountants of India FCA, an Associate of the Institute of Chartered Accountants of Barbados and a qualified Company Secretary from the Institute of Company Secretaries of India. He has over 21 years of experience in the areas of financial accounting, management and audit in several parts of the world, including at senior positions with big 4 audit firms as well as senior finance management positions at multinational companies. Prior to joining the Corporation in July 2015 he was based in India as the Head of Finance of the South Asia & Middle East Division of SMEC, an Australian engineering consultancy multinational for the past two -2 years. Prior to that, he was an Audit Director with PricewaterhouseCoopers LLP in Barbados. His previous work experiences include that as Group Financial Controller of Cordlife, a stem cell biotechnology & healthcare group, in Singapore/ Australia, Audit Supervisor at KPMG in Oman, Audit Senior at KPMG in Singapore, Senior Executive Accounts at Siemens in India & Audit Assistant at Coopers & Lybrand in India.- Arijit Mookerjee，他是CPL公司的董事总经理兼首席财务官。他是the Institute of Chartered Accountants of India FCA的成员、the Institute of Chartered Accountants of Barbados的副合伙人、the Institute of Company Secretaries of India的合格公司秘书。他拥有超过21年的财务会计、管理和审计的领域经验，包括担任4大审计公司的高级职务，以及跨国公司的高级财务管理职务。2015年7月加入公司之前，他曾担任在印度担任 SMEC（澳大利亚工程咨询公司、跨国公司）的南亚和中东金融部门的财务主管，任职2年。此前，他曾担任PricewaterhouseCoopers公司（位于巴巴多斯）的审计主管。他此前曾担任Cordlife公司（干细胞生物技术和医疗集团，位于新加坡和澳大利亚）的集团财务总会计师、KPMG公司（位于阿曼）的审计监察员、KPMG公司（位于新加坡）的高级审计师、Siemens公司（位于印度）的高级账户执行官、Coopers & Lybrand（位于印度）的审计助理。
- Arijit Mookerjee is the Managing Director and Chief Financial Officer of CPI. Mr. Mookerjee is a Fellow of the Institute of Chartered Accountants of India FCA, an Associate of the Institute of Chartered Accountants of Barbados and a qualified Company Secretary from the Institute of Company Secretaries of India. He has over 21 years of experience in the areas of financial accounting, management and audit in several parts of the world, including at senior positions with big 4 audit firms as well as senior finance management positions at multinational companies. Prior to joining the Corporation in July 2015 he was based in India as the Head of Finance of the South Asia & Middle East Division of SMEC, an Australian engineering consultancy multinational for the past two -2 years. Prior to that, he was an Audit Director with PricewaterhouseCoopers LLP in Barbados. His previous work experiences include that as Group Financial Controller of Cordlife, a stem cell biotechnology & healthcare group, in Singapore/ Australia, Audit Supervisor at KPMG in Oman, Audit Senior at KPMG in Singapore, Senior Executive Accounts at Siemens in India & Audit Assistant at Coopers & Lybrand in India.
- Graeme Duncan
Graeme Duncan是Concordia国际业务部门的总裁。邓肯先生于2014年加入安科，担任英国和爱尔兰商业全球营销总监兼Vice President。他于2016年被提拔为董事总经理，现负责该分部的综合管理。邓肯先生在生命科学领域的战略、销售与市场营销和管理领域工作了20年。在加入该公司之前，邓肯先生曾在葛兰素史克公司、葛兰素史克公司、IVAX制药公司和梦百合公司担任高级管理职务。
Graeme Duncan is the President of the Concordia International operating segment. Mr. Duncan joined AMCo in 2014 as Global Marketing Director and Vice President, Commercial UK and Ireland. He was promoted to Managing Director in 2016 and is now responsible for the general management of the segment. Mr. Duncan has worked for 20 years in the life sciences sector within the areas of strategy, sales and marketing, and management. Prior to joining the Corporation, Mr. Duncan held senior management roles in GlaxoWellcome, GlaxoSmithKline, IVAX Pharmaceuticals and Healthcare at Home.- Graeme Duncan是Concordia国际业务部门的总裁。邓肯先生于2014年加入安科，担任英国和爱尔兰商业全球营销总监兼Vice President。他于2016年被提拔为董事总经理，现负责该分部的综合管理。邓肯先生在生命科学领域的战略、销售与市场营销和管理领域工作了20年。在加入该公司之前，邓肯先生曾在葛兰素史克公司、葛兰素史克公司、IVAX制药公司和梦百合公司担任高级管理职务。
- Graeme Duncan is the President of the Concordia International operating segment. Mr. Duncan joined AMCo in 2014 as Global Marketing Director and Vice President, Commercial UK and Ireland. He was promoted to Managing Director in 2016 and is now responsible for the general management of the segment. Mr. Duncan has worked for 20 years in the life sciences sector within the areas of strategy, sales and marketing, and management. Prior to joining the Corporation, Mr. Duncan held senior management roles in GlaxoWellcome, GlaxoSmithKline, IVAX Pharmaceuticals and Healthcare at Home.
- Allan Oberman
Allan Oberman在2012年11月成为Teva Americas Generics的总裁兼首席执行官（在2012年间担任Teva北美仿制药部门的主管之后）。他从2010年至2012年担任Teva EMIA的总裁，负责东欧，中东，以色列和非洲。从2008年到2010年他担任Teva International Group的首席运营官。他从2000年到2008年担任Novopharm Ltd.（目前是Teva Canada）的总裁兼首席执行官。加入Teva之前，他从1996年到2000年是Best Foods Canada Inc.的总裁。他持有约克大学舒立克商学院（Schulich School of Business, York University）的工商管理硕士学位和西安大略大学（University of Western Ontario）的学士学位。
Allan Oberman has been a member of our Board of Directors since March 2019. Mr. Allan Oberman served as the Chief Executive Officer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and as President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Allan Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010 he served as the Chief Operating Officer of the Teva International Group, and from 2000 to 2008 he served as the President and CEO of Teva Canada formerly Novopharm Ltd. From 1996 to 2000 Mr. Allan Oberman was the President of Best Foods Canada Inc. Mr. Allan Oberman was also Vice Chairman of the Association for Accessible Medicines, and Chairman of the Canadian Generic Pharmaceutical Association. He served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. He presently serves on the Board of Planet Shrimp Inc. and Jay Pharma Inc. He holds a MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London.- Allan Oberman在2012年11月成为Teva Americas Generics的总裁兼首席执行官（在2012年间担任Teva北美仿制药部门的主管之后）。他从2010年至2012年担任Teva EMIA的总裁，负责东欧，中东，以色列和非洲。从2008年到2010年他担任Teva International Group的首席运营官。他从2000年到2008年担任Novopharm Ltd.（目前是Teva Canada）的总裁兼首席执行官。加入Teva之前，他从1996年到2000年是Best Foods Canada Inc.的总裁。他持有约克大学舒立克商学院（Schulich School of Business, York University）的工商管理硕士学位和西安大略大学（University of Western Ontario）的学士学位。
- Allan Oberman has been a member of our Board of Directors since March 2019. Mr. Allan Oberman served as the Chief Executive Officer of Concordia International Corp. from November 2016 until May 2018. In his career of more than 35 years he also served as CEO of Sagent Pharmaceuticals Inc., and as President and CEO of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Allan Oberman served as President of Teva EMIA, where from 2010 to 2012 he was responsible for Eastern Europe, Middle East, Israel and Africa. From 2008 to 2010 he served as the Chief Operating Officer of the Teva International Group, and from 2000 to 2008 he served as the President and CEO of Teva Canada formerly Novopharm Ltd. From 1996 to 2000 Mr. Allan Oberman was the President of Best Foods Canada Inc. Mr. Allan Oberman was also Vice Chairman of the Association for Accessible Medicines, and Chairman of the Canadian Generic Pharmaceutical Association. He served on the Associate Board of the Canadian Association of Chain Drug Stores, and was a member of the Board of Directors of the Baycrest Centre Foundation, the Electronic Commerce Council, and the Food and Consumer Products Association of Canada. He presently serves on the Board of Planet Shrimp Inc. and Jay Pharma Inc. He holds a MBA from the Schulich School of Business, York University, Toronto and a BA from Western University, London.